Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05660980 · ClinicalTrials.gov registry record · Phase 1
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
A Phase 1 study of HIV-1-infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 12
- Study locations
NCT05660980 is a Phase 1 study of HIV-1-infection that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 90 participants, below the 350-participant average among 71 other HIV-1-infection trials with a reported enrollment target (74% lower). The trial reports 12 study locations across 5 states.
The verdict
NCT05660980, a Phase 1 study of HIV-1-infection, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, tolerability, and acceptability of a long-acting injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age
Conditions Studied
Interventions
- DRUG Once daily CAB tablet + RPV tablet
- DRUG Long acting CAB injectable + long acting RPV injectable
Study Locations (12)
Other
- Site 12701, Gaborone CRS - Gaborone
- Site 12702, Molepolole CRS - Gaborone
- Site 5073, SOM Federal University Minas Gerais Brazil NICHD CRS - Belo Horizonte
- CRS 5071, Instituto de Puericultura e Pediatria Martagao Gesteira Clinical Research Site - Rio de Janeiro
- Site 8051, Wits RHI Shandukani Research Centre CRS - Johannesburg
- CRS 8052, Soweto IMPAACT - Johannesburg
- CRS 31784, Chiang Mai University HIV Treatment CRS - Chiang Mai
- Site 5116, PHPT-Chiangrai Prachanukroh Hospital NICHD CRS - Chiang Rai
Georgia
- Site 5030, Emory University School of Medicine NICHD CRS - Atlanta
Tennessee
- Site 6501, St. Jude Children's Research Hospital CRS - Memphis
KwaZulu-Natal
- Site 30300 Umlazi CRS Site - Umlazi
Bangkoknoi
- Siriraj Hospital, Mahidol University NICHD CRS (Site #5115) - Bangkok
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-01-24 |
| Est. Completion | 2027-07-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05660980
The ClinicalTrials.gov registry entry for NCT05660980 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 350-participant average among 71 other HIV-1-infection trials with a reported enrollment target (74% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 2 interventions - of which Once daily CAB tablet + RPV tablet is the first listed.
NCT05660980 reports 12 study locations spanning 5 distinct geographic areas - top geographies include Other, Georgia, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05660980 about?
NCT05660980 is a clinical study titled "Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age". The purpose of the study is to evaluate the pharmacokinetics (PK), safety, tolerability, and acceptability of a long-acting injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age
What is the current status of trial NCT05660980?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2024-01-24. Estimated completion is 2027-07-27.
What conditions does trial NCT05660980 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT05660980?
The interventions under investigation include: Once daily CAB tablet + RPV tablet (DRUG), Long acting CAB injectable + long acting RPV injectable (DRUG).
Who is sponsoring clinical trial NCT05660980?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05660980 being conducted?
This trial has 12 study locations across Georgia, Tennessee, KwaZulu-Natal, Bangkoknoi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of GS-3242 in Participants With HIV-1; Substudy-05
RECRUITING · Phase 1
-
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
RECRUITING · Phase 1
-
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
RECRUITING · Phase 1
-
PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)
RECRUITING · Phase 1
-
Safety Study of MucoCept-CVN
RECRUITING · Phase 1
-
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.